Humanised antibodies, TRX1 include modified constant regions and light and heavy chain framework of human antibody and CDR regions derived from a mouse monoclonal antibody. TRX1 binds to an epitope of a CD4 antigen on CD4 positive human T-cells or monocytes. The antibodies are designed such that they may or may not include (i) CDRs that are free from glycosylation sites or (ii) do not bind the Fc region of the receptor. Also claimed is a method of treating a graft transplant patient by administering such antibodies thereby inhibiting an immune response and preventing rejection.
FREWIN MARK [GB]; WALDMANN HERMAN [GB]; GORMAN SCOTT [GB]; HALE GEOFF [GB]; RAO PATRICIA [US]; KORNAGA TADEUSZ [US]; RINGLER DOU
Type of Offer:
« More Biotech Patents